This article is more than 5 years old. Information may no longer be current.
SARIS: Intracranial stenting aids in recanalization
All patients in the study population achieved recanalization and TIMI flow improvement.
Click Here to Manage Email Alerts
Results from a pilot study suggested that intracranial stenting may be associated with improved outcomes in patients with intracranial occlusions.
The FDA-approved pilot study SARIS included 20 patients who presented within eight hours of stroke onset. The researchers evaluated the safety of intracranial stenting using the Wingspan stent (Boston Scientific), which is currently the only FDA-approved stent for use in brain arteries.
According to the study abstract, the mean presenting NIH Stroke Scale score was 14. The presenting thrombolysis in MI scores of all patients were either zero (85%) or one (15%). The researchers reported that all 20 patients achieved recanalization following the stenting procedure, with 60% of the patients achieving TIMI 3 flow levels (P<.0001). Improvement in NIH Stroke Scale scores was also reported in 85% of the patients, with 65% improving by at least four points. The median improvement in NIH Stroke Scale scores from intervention to discharge was nine points (P<.001).
“We certainly do not know if stents are the answer to this problem,” J.D. Mocco, MD, clinical assistant professor of neurology at the State University of New York in Buffalo, said in his presentation at the International Stroke Conference. “The data certainly does not prove it at this point, but based on this data, the FDA has approved an additional 20-patient extension to continue this prospective data collection, and it will hopefully lead to a clinical trial.”
For more information:
- Mocco J. #144. Presented at American Stroke Association International Stroke Conference 2009; February 17-20, 2009; San Diego.
